Log In
BCIQ
Print this Print this
 

EncorStat (OXB-202)

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionLentiVector-based gene therapy
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPreclinical
Standard IndicationCorneal transplant
Indication DetailsPrevent corneal graft rejection
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$26.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/04/2009

Undisclosed

$26.0M

Undisclosed

Get a free BioCentury trial today